Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$0.76 -1.8%	$0.83	$0.55 ▼ $1.66	$98.36M	0.92	856,423 shs	457,184 shs
CNTB Connect Biopharma	$1.78 +2.9%	$1.65	$0.51 ▼ $2.86	$99.18M	-0.09	113,791 shs	117,700 shs
EMBI Emerald Bioscience		$0.00	$0.02 ▼ $0.20	$24.13M	0.43	14.24 million shs	6.96 million shs
ZOM Zomedica		$0.12	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+2.04%	+3.37%	-7.69%	-4.66%	-46.53%
CNTB Connect Biopharma	-7.49%	-4.42%	-22.07%	+121.82%	+69.61%
EMBI Emerald Bioscience	0.00%	0.00%	0.00%	0.00%	0.00%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	-28.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Genetics	2.5097 of 5 stars	3.7	5.0	0.0	0.0	2.2	0.0	0.0
CNTB Connect Biopharma	3.4166 of 5 stars	3.8	5.0	0.0	0.0	2.8	2.5	0.0
EMBI Emerald Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	3.33	Buy	$6.17	709.81% Upside
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	293.26% Upside
EMBI Emerald Bioscience	0.00	N/A	N/A	N/A
ZOM Zomedica	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest EMBI, CNTB, ATOS, and ZOM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.45 per share	N/A
CNTB Connect Biopharma	$26.03M	3.81	N/A	N/A	$1.28 per share	1.39
EMBI Emerald Bioscience	N/A	N/A	N/A	1.20	N/A	N/A
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$25.50M	-$0.23	N/A	N/A	N/A	N/A	-40.28%	-37.10%	11/11/2025 (Estimated)
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
EMBI Emerald Bioscience	$1.05M	-$0.08	N/A	N/A	N/A	N/A	N/A	-347.62%	N/A
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest EMBI, CNTB, ATOS, and ZOM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ATOS Atossa Genetics	-$0.06	-$0.07	-$0.01	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
EMBI Emerald Bioscience	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	9.17	9.17
CNTB Connect Biopharma	0.01	7.24	7.24
EMBI Emerald Bioscience	0.43	3.59	3.59
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
CNTB Connect Biopharma	58.72%
EMBI Emerald Bioscience	5.58%
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	8.70%
CNTB Connect Biopharma	22.60%
EMBI Emerald Bioscience	1.60%
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
EMBI Emerald Bioscience	4	268.07 million	N/A	Not Optionable
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

EMBI, CNTB, ATOS, and ZOM Headlines

Recent News About These Companies

Zomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19, 2025 | finanznachrichten.de

Zomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

August 12, 2025 | finanznachrichten.de

Zomedica Achieves Record Revenue Growth in Q2 2025

August 6, 2025 | msn.com

Non-Pharmacologic Solutions for Pet Dental Health From Prevention to Recovery

July 11, 2025 | dvm360.comD

Zomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - Ocala

July 10, 2025 | finanznachrichten.de

Zomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - Morningstar

June 25, 2025 | morningstar.comM

Zomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

May 20, 2025 | finanznachrichten.de

Treat pet pain, inflammation, and anxiety with this high-tech at home therapy

April 24, 2025 | click2houston.comC

Helping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family Members

April 11, 2025 | pix11.comP

Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?

March 28, 2025 | insidermonkey.com

15 Cheapest Stocks Insiders Are Buying In March

March 27, 2025 | insidermonkey.com

Earnings call transcript: Zomedica Q4 2024 shows revenue growth

March 15, 2025 | investing.com

Q4 2024 Zomedica Corp Earnings Call

March 15, 2025 | finance.yahoo.com

Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript

March 13, 2025 | seekingalpha.com

Zomedica (ZOMDF) Gets a Buy from Noble Financial

March 11, 2025 | markets.businessinsider.com

Zomedica Corp.

March 8, 2025 | wsj.com

Zomedica Corp. Announces Transition to OTCQB Venture Market

March 4, 2025 | accessnewswire.comA

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

March 4, 2025 | businesswire.com

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

February 26, 2025 | accessnewswire.comA

Zomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EMBI, CNTB, ATOS, and ZOM Company Descriptions

Atossa Genetics NASDAQ:ATOS

$0.76 -0.01 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$0.78 +0.02 (+2.17%)

As of 05:48 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Connect Biopharma NASDAQ:CNTB

$1.78 +0.05 (+2.89%)

Closing price 04:00 PM Eastern

Extended Trading

$1.77 -0.01 (-0.56%)

As of 05:16 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Emerald Bioscience OTCMKTS:EMBI

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time